ALGN Stock Rises Premarket After Elliott Reportedly Builds ‘Significant’ Stake In Invisalign-Maker

• Elliott is planning to engage with the dental company to encourage it to explore ways to boost its stock price.
• ALGN stock is down 75% from its record high in September 2021.
• Stocktwits sentiment for ALGN turns ‘bullish.’

Shares of Align Technology, Inc. jumped 4% in early premarket trading on Thursday after a report said that activist investor Elliott Investment Management had built a “significant stake” in the maker of Invisalign teeth-straightening products.

Elliott, now one of Align's largest investors, is planning to engage with the dental company to encourage it to explore ways to boost its stock price, Bloomberg reported late Wednesday, citing people familiar with the matter.

Align is a global leader in clear aligners, best known for its Invisalign system, and holds a dominant position in digital orthodontics alongside its iTero 3D dental scanner. 

Stock Has Been Dull

The company has maintained low single-digit percentage growth in the last three years and recently guided for a modest 3–4% revenue growth in 2026, driven by international expansion and continued adoption of Invisalign.

But ALGN stock has fared poorly, down about 75% from its September 2021 peak. Currently, 11 out of 17 analysts recommend a ‘Buy’ or higher on shares, five rate it ‘Hold,’ and one rates it ‘Strong Sell,’ per Koyfin. They, on average, project an upside of 17% in the next 12 months.

In an investor note, earlier this week, Barclays said that shares of Align, which has a manufacturing facility in Israel, should regain some of the value lost since the war with Iran began. 

They argued that the stock trades at around 12 times its earnings before interest, taxes, depreciation, and amortization, up from the current multiple of 10 times its estimated 2027 Ebitda. That compares with three- and five-year historical average multiples of 17 and 21, respectively.

Retail’s View On ALGN

On Stocktwits, retail sentiment for ALGN was ‘bullish’ as of early Thursday, climbing up from ‘neutral’ at the start of the week. 

Elliott’s Hold In Health Services

Elliott has invested in healthcare firms, including Charles River Laboratories, which struck a cooperation deal and refreshed its board, and Catalent, which was sold to Novo Holdings. The investor exited Cardinal Health in late 2024 after securing a board seat.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: OSS Stock Extends Rally To Third Day As Defense Contracts, $22M Divestiture Drive Profitability, Record Margins